But these light - sensitive neurons get some help from a much
rarer kind of cell, according to a new study.
Not exact matches
This unfortunate and
rare side effect
of the biopsy provided Nicola Valeri at the Institute
of Cancer Research in London and his colleagues with a
kind of stopwatch — an exact point in time when a few
cells left as the needle was withdrawn began their two year evolution into a tumour.
Jonathan Appleby, GSK project leader for the ADA - SCID trial and head
of cell and gene therapy at the
rare diseases unit, says there are many differences between working on this
kind of trial and working with one for a common disease.
For a single tumor to possess more than one
kind of cancerous
cell is actually
rare in many species.